Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review Ricardo L. B. CostaHyo Sook HanWilliam J. Gradishar Review 07 February 2018 Pages: 397 - 406
First international TNBC conference meeting report Padmashree RidaAngela OgdenRitu Aneja Review 08 February 2018 Pages: 407 - 412
Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis Hadar GoldvaserHabeeb MajeedEitan Amir Review 08 February 2018 Pages: 413 - 425
Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes Neda ZareiMehdi FazeliForoogh Nejatollahi Preclinical study 06 February 2018 Pages: 427 - 436
Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer Kanae K. MiyakeYuji NakamotoKaori Togashi Preclinical study 08 February 2018 Pages: 437 - 446
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy Yuri TolkachHeidrun GevenslebenGlen Kristiansen Preclinical study 17 February 2018 Pages: 447 - 455
A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer M. RudolphS. T. SizemoreB. Ramaswamy Preclinical study 20 February 2018 Pages: 457 - 467
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial Wolfgang JanniEmilio AlbaMario Campone Clinical trial 05 February 2018 Pages: 469 - 479
Breast cancer subtype and survival by parity and time since last birth H. De MulderA. LaenenP. Neven Clinical trial 10 February 2018 Pages: 481 - 487
Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial Per SkaaneSofie SebuødegårdSolveig Hofvind Clinical trial 10 February 2018 Pages: 489 - 496
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial Kim C. AaldersNathan Touation behalf of the EORTC 10994/BIG 1-00 Study Investigators Clinical trial 12 February 2018 Pages: 497 - 505
Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy Ji Hyun ChangKyung Hwan ShinSuzy Kim Clinical trial 12 February 2018 Pages: 507 - 512
The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery Angela CollarinoRenato A. Valdés OlmosLenka M. Pereira Arias-Bouda Clinical trial Open access 13 February 2018 Pages: 513 - 522
Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer Farrokh DehdashtiNingying WuBarry A. Siegel Clinical trial 13 February 2018 Pages: 523 - 530
Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study James R. HarveyYit LimAnthony J. Maxwell Clinical trial Open access 16 February 2018 Pages: 531 - 536
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03) Lynne I. WagnerFengmin ZhaoDavid Cella Clinical trial 17 February 2018 Pages: 537 - 548
Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients D. H. M. JacobsG. SpeijerP. C. M. Koper Clinical trial Open access 19 February 2018 Pages: 549 - 559
Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers Jacqueline LammertJan LubinskiJoanne Kotsopoulos Epidemiology 05 February 2018 Pages: 561 - 571
Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18–64 years in BCBS of Texas Junghyun KimSuja S. RajanRobert O. Morgan Epidemiology 08 February 2018 Pages: 573 - 586
A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis Vasily GiannakeasVictoria SopikSteven A. Narod Epidemiology 14 February 2018 Pages: 587 - 594
Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013 Meredith L. ShoemakerMary C. WhiteIsabelle Romieu Epidemiology 14 February 2018 Pages: 595 - 606
Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population Catherine SchairerD. Michal FreedmanRuth M. Pfeiffer Epidemiology 15 February 2018 Pages: 607 - 614
Factors associated with improved outcomes for metastatic inflammatory breast cancer patients Anna WeissRhiana S. MenenGildy Babiera Epidemiology 19 February 2018 Pages: 615 - 623
MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine Bingbing XieZifeng YuanXiangdong Fang Brief Report 10 February 2018 Pages: 625 - 632
Is invasion a necessary step for metastases in breast cancer? Narod SA, Sopik V Alan B. Hollingsworth Letter to the Editor 12 February 2018 Pages: 633 - 637
Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass? Steven A. Narod Rebuttal Letter 14 March 2018 Pages: 639 - 640
